Weekly Spotlight - 12.12.24

Patient Stories

Maddox Cove Woman Life Transformed by Compassionate Liver Donation

Janet Hong from Maddox Cove has been given a new lease on life following a successful liver transplant. Diagnosed with PBC at 29, she faced a grim prognosis without a live donor. Her story took a hopeful turn when Carlene Paquette, a compassionate soul from Ottawa, stepped forward to donate part of her liver. This act of kindness has not only saved Hong life but also forged a lasting bond between the two women, with Paquette now considered family.

Hong journey underscores the profound impact of human compassion and community support. After years of battling, she is now on the road to recovery, embracing new opportunities for health and vitality. Her story is a testament to the power of generosity and the resilience of the human spirit. As she recovers in Edmonton, Hong looks forward to returning to Newfoundland and eventually visiting her property in Florida, buoyed by the love and support she has received.

Community News

New Hope for Pruritus Relief in Primary Biliary Cholangitis Patients

The article discusses the impact of pruritus in Primary Biliary Cholangitis (PBC) and the introduction of seladelpar as a new treatment. Pruritus significantly affects patients quality of life, causing sleep disruption and emotional strain. Seladelpar offers hope, showing promise in reducing these symptoms and improving patient well-being.

Ocaliva EU Withdrawal: Impact on PBC Patients and Future Prospects

Ocaliva, a treatment for primary biliary cholangitis, has been withdrawn from the EU market following a court decision. Despite Advanz Pharma efforts to maintain its availability, the European Commission revocation stands. Patients may still access it through special programmes, highlighting ongoing support for those affected.

Research Spotlight

Exploring the Link Between Gut Health and Liver Disease: New Insights Unveiled

Mendelian randomization reveals a causal link between inflammatory bowel disease (IBD) and primary biliary cholangitis (PBC). The study highlights Crohn disease as a significant IBD subtype increasing PBC risk. These findings underscore the importance of proactive PBC prevention in IBD patients, especially those with Crohn disease.

Exploring New Horizons: Second-Line Treatments for Primary Biliary Cholangitis

Primary biliary cholangitis treatment has long relied on ursodeoxycholic acid (UDCA). However, with 40% of patients not responding adequately, second-line therapies are essential. This shift highlights the need for alternative treatments, sparking curiosity about emerging options and their potential to improve patient outcomes.